Related Experiment Video
Updated: Dec 31, 2025

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
Mucopolysaccharidosis-Plus Syndrome
Filipp Vasilev1,2,3, Aitalina Sukhomyasova3, Takanobu Otomo1
1Department of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki, Okayama 701-0192, Japan.
Abstract:
Previously, we reported a novel disease of impaired glycosaminoglycans (GAGs) metabolism without deficiency of known lysosomal enzymes-mucopolysaccharidosis-plus syndrome (MPSPS). MPSPS, whose pathophysiology is not elucidated, is an autosomal recessive multisystem disorder caused by a specific mutation p.R498W in the VPS33A gene. VPS33A functions in endocytic and autophagic pathways, but p.R498W mutation did not affect both of these pathways in the patient's skin fibroblast. Nineteen patients with MPSPS have been identified: seventeen patients were found among the Yakut population (Russia) and two patients from Turkey. Clinical features of MPSPS patients are similar to conventional mucopolysaccharidoses (MPS). In addition to typical symptoms for conventional MPS, MPSPS patients developed other features such as congenital heart defects, renal and hematopoietic disorders. Diagnosis generally requires evidence of clinical picture similar to MPS and molecular genetic testing. Disease is very severe, prognosis is unfavorable and most of patients died at age of 10-20 months. Currently there is no specific therapy for this disease and clinical management is limited to supportive and symptomatic treatment.
Insights
Mucopolysaccharidosis-plus syndrome (MPSPS) is a severe genetic disorder caused by a VPS33A mutation, affecting glycosaminoglycan metabolism. Early diagnosis and supportive care are crucial due to the unfavorable prognosis and lack of specific therapies.
Area of Science:
- Genetics
- Biochemistry
- Rare Diseases
Background:
- Mucopolysaccharidosis-plus syndrome (MPSPS) is a novel genetic disorder characterized by impaired glycosaminoglycan (GAG) metabolism.
- Unlike conventional mucopolysaccharidoses (MPS), MPSPS is not caused by deficiencies in known lysosomal enzymes.
Observation:
- MPSPS is an autosomal recessive multisystem disorder linked to the p.R498W mutation in the VPS33A gene.
- The VPS33A p.R498W mutation does not appear to affect endocytic or autophagic pathways in patient fibroblasts.
- Nineteen cases have been identified, predominantly in the Yakut population of Russia, with two cases from Turkey.
Findings:
- MPSPS patients exhibit clinical features overlapping with conventional MPS, alongside additional complications like congenital heart defects, and renal and hematopoietic disorders.
- Diagnosis relies on clinical presentation resembling MPS and confirmed molecular genetic testing for the VPS33A mutation.
Implications:
- The severe nature of MPSPS, with a high mortality rate in infancy (10-20 months), highlights the urgent need for further research.
- Current management is limited to supportive and symptomatic treatment, emphasizing the critical need for developing specific therapies for this rare genetic condition.
Related Concept Videos
Proteoglycans
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Lysosomal Hydrolases
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Biosynthesis of Polysaccharides

